U.S. FDA Accepts Karyopharm ’s New Drug Application for Selinexor and Grants Priority Review

NEWTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news